MSMara Lúcia Gomes de Souza

Mara Lúcia Gomes de Souza

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Mara Lúcia Gomes de Souza has a total of 40 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Caspase-1 Variants and Plasma IL-1β in Patients with Leishmania guyanensis Cutaneous Leishmaniasis in the Amazonas

    by Josué Lacerda de Souza, Marcus Vinitius de Farias Guerra, Tirza Gabrielle Ramos de Mesquita, José Do Espírito Santo Junior, Hector David Graterol Sequera, Lener Santos da Silva, Larissa Almeida da Silva, Filipe Menezes Moura, Lizandra Stephanny Fernandes Menescal, Júlia da Costa Torres, et al.

    Leishmaniasis, a disease caused by protozoan Leishmania spp., exhibits a broad range of clinical manifestations. Host resistance or susceptibility to infections is often influenced by the genetic make-up associated with natural immunity. Caspase-1, a key component of the NLRP3 inflammasome, is critical for processing pro-IL-1β into its active form, IL-1β, while CARD8 functions as an NLRP3 inflammasome inhibitor. We conducted a case–control study comparing L. guyanensis-cutaneous leishmaniasis (Lg-CL) patients with healthy individuals (HCs) by analyzing the CASP1 genetic variants rs530537A>G, rs531542C>T, rs531604A>T and rs560880G>T. Additionally, a combined analysis of CARD8rs2043211A>T with CASP1rs530537 was performed. The genotype distribution for the four variants showed no significant differences between Lg-CL patients and HCs. However, the haplotype analysis of the four CASP1 variants identified the GTTT haplotype as associated with a 19% decreased likelihood of Lg-CL development, suggesting a protective effect against disease progression. The combined analysis of CARD8 with CASP1 variants indicated that individuals homozygous for both variants (GG/TT) exhibited a 38% reduced risk of developing Lg-CL (OR = 0.62 [95%CI:0.46–0.83]) in comparison to individuals with other genotype combinations. No correlation was found between the CASP1 variant genotypes and plasma IL-1β levels. CASP1 may act as a genetic modifier in Lg-CL.

  • Open Access

    Lobomicose: apresentação exuberante com transformação maligna

    by Wanessa da Costa Lima, Sidharta Quercia Gadelha, Mara Lúcia Gomes de Souza, Virginia Vilasboas Figueiras

  • Open Access

    Lobomycosis: exuberant presentation with malignant transformation

    by Wanessa da Costa Lima, Sidharta Quercia Gadelha, Mara Lúcia Gomes de Souza, Virginia Vilasboas Figueiras


  • Open Access

    Variants of MIRNA146A rs2910164 and MIRNA499 rs3746444 are associated with the development of cutaneous leishmaniasis caused by Leishmania guyanensis and with plasma chemokine IL-8

    by Tirza Gabrielle Ramos de Mesquita, José Do Espírito Santo Junior, Thais Carneiro de Lacerda, Krys Layane Guimarães Duarte Queiroz, Cláudio Marcello da Silveira Júnior, José Pereira de Moura Neto, Lissianne Augusta Matos Gomes, Mara Lúcia Gomes de Souza, Marcus Vinitius de Farias Guerra, Rajendranath Ramasawmy

    Leishmaniaare intracellular protozoan parasites that cause a wide spectrum of clinical manifestations in genetically susceptible individuals with an insufficient or balanced Th1 immune response to eliminate the parasite. MiRNAs play important regulatory role in numerous biological processes including essential cellular functions. miR146-a acts as an inhibitor of interleukin 1 receptor associated kinase 1 (IRAK1) and tumour necrosis factor (TNF) receptor associated factor 6 (TRAF6) present in the toll-like receptors pathway while miR499a modulates TGF-β and TNF signalling pathways. Here, we investigated whetherMIRNA146A rs2910164 and MIRNA499 rs3746444variants are associated with the development ofL.guyanensis(Lg)-cutaneous leishmaniasis (CL). The variantsMIR146Ars2910164 andMIR499Ars3746444 were assessed in 850 patients withLg-CL and 891 healthy controls by polymerase chain reaction and restriction fragment length polymorphism (PCR-RFLP). Plasma cytokines were measured using the BioPlex assay. Carriers of rs2910164 CC genotype have 30% higher odds of developing CL (ORadjage/sex= 1.3 [95%CI 0.9–1.8]; Padjage/sex0.14) compared to individuals with the genotype GG (ORadjage/sex= 0.77 [95%CI 0.56–1.0]; Padjage/sex0.14) if exposed toLg-infection. Heterozygous GC individuals also showed lower odds of developing CL (ORadjage/sex= 0.77 [95%CI 0.5–1.1]; Padjage/sex0.09). Homozygosity for the allele C is suggestive of an association with the development ofLg-CL among exposed individuals toLg-infection. However, the odds of developing CL associated with the CC genotype was evident only in male individuals (ORadjage= 1.3 [95% CI = 0.9–2.0]; Padjage= 0.06). Individuals homozygous for the G allele tend to have higher plasma IL-8 and CCL5. Similarly, for theMIR499Ars3746444, an association with the G allele was only observed among male individuals (OR = 1.4 [1.0–1.9]; P = 0.009). In a dominant model, individuals with the G allele (GG-GA) when compared to the AA genotype reveals that carriers of the G allele have 40% elevated odds of developingLg-CL (ORadjage= 1.4 [1.1–1.9]). Individuals with the GG genotype have higher odds of developingLg-CL (ORadjage/sex= 2.0 [95%CI 0.83–5.0]; Padjage= 0.01. Individuals homozygous for the G allele have higher plasma IL-8. Genetic combinations of both variants revealed that male individuals exposed toLgbearing three or four susceptible alleles have higher odds of developingLg-CL (OR = 2.3 [95% CI 1.0–4.7]; p = 0.017). BothMIR146Ars2910164 andMIR499Ars3746444 are associated with the development ofLg-CL and this association is prevalent in male individuals.


  • Open Access

    Discoid Lupus Erythematosus of the Scalp in a Patient with Systemic Lupus Erythematosus: A Case Report with Complete Hair Regrowth

    by Cleide Garbelini-Lima, Gabriela Evangelista de Almeida, Sidharta Quércia Gabdelha, Andrea Cavalcante de Souza, Mara Lúcia Gomes de Souza, Virginia Vilasboas Figueiras

    Scalp involvement with hair loss is common in systemic lupus erythematosus. Discoid lupus erythematosus may cause scarring alopecia, characterized by well-delimited erythematous plaques with scales, follicular hyperkeratosis and atrophy, which is considered a trichological emergency. Early diagnosis and treatment are necessary in order to prevent permanent hair loss. We describe a 44 years’ old female patient with systemic lupus erythematosus for 4 years, with multiple areas of occipitoparietal alopecia, erythematous plaques, atrophy, scales and some bloody crusts. Trichoscopy, histopathology and direct immunofluorescence led to the diagnosis of discoid lupus erythematosus. After 9 months treatment with thalidomide there was complete hair regrowth.


  • Open Access

    TREM1 rs2234237 (Thr25Ser) Polymorphism in Patients with Cutaneous Leishmaniasis Caused by Leishmania guyanensis: A Case-Control Study in the State of Amazonas, Brazil

    by José Do Espírito Santo Júnior, Tirza Gabrielle Ramos de Mesquita, Luan Diego Oliveira da Silva, Felipe Jules de Araújo, Josué Lacerda de Souza, Thaís Carneiro de Lacerda, Lener Santos da Silva, Cláudio Marcello da Silveira Júnior, Krys Layane Guimarães Duarte Queiroz, Diogo Matos dos Santos, et al.

    Background: Leishmaniasis is an infectious disease caused by Leishmania parasites. A Th1 immune response is necessary in the acute phase to control the pathogen. The triggering receptor expressed on myeloid cells (TREM)-1 is a potent amplifier of inflammation. Our aim is to identify whether the TREM1 variant rs2234237 A/T (Thr25Ser) is associated with the disease development of cutaneous leishmaniasis (CL) in Leishmania guyanensis-infected individuals. The effects of the rs2234237 genotypes on plasma cytokines IL-1β, IL-6, IL-8, IL-10, MCP-1 and TNF-α are also investigated. Methods: 838 patients with CL and 818 healthy controls (HCs) living in the same endemic areas were genotyped by Polymerase Chain Reaction-Restriction Fragment Length Polymorphism. Plasma cytokines were assayed in 400 patients with CL and 400 HCs using the BioPlex assay. Results: The genotypes’ and alleles’ frequencies were similar in both patients with CL (AA = 618, 74%; AT = 202, 24%; TT = 18, 2%) and in HCs (AA = 580, 71%; AT = 220, 27%; TT = 18, 2%). Rs2234237 showed a modest effect on plasma IL-10 that disappeared when correction of the p-value was applied. Plasma IL-10 by rs2234237 genotypes were (mean ± SEM; AA = 2.91 pg/mL ± 0.14; AT = 2.35 pg/mL ± 0.12; TT = 3.14 pg/mL ± 0.56; p = 0.05). Conclusion: The TREM1 rs2234237 (Thr25Ser) seems to have no influence on the susceptibility or resistance to L. guyanensis infections.


  • Open Access

    Keloid-like lesions in a farmer from Amazonas

    by Sidharta Quercia Gadelha, Gabriela Evangelista de Almeida, Alcidarta dos Reis Gadelha, Mara Lúcia Gomes de Souza, Virginia Vilasboas Figueiras


  • Open Access

    Exuberant oral lesions in an immunocompromised patient

    by Cleide Garbelini Lima Forneck, Gabriela Evangelista de Almeida, Marcela Carolina Pastore, Andréa de Souza Cavalcante, Mara Lúcia Gomes de Souza